The Ministry of Health is set to launch the nationwide rollout of the R21/Matrix-M malaria vaccine, a historic breakthrough after more than three decades of global efforts to develop an effective vaccine against the disease.
With malaria being one of Uganda's leading public health challenges, this vaccine offers a crucial step in reducing illness and deaths, particularly among children under five.
Malaria remains a major burden in Uganda, with the entire population at risk of infection.
The disease accounts for 30 to 50 percent of outpatient visits and 15 to 20 percent of hospital admissions, making it the leading cause of death among young children.
"The impact of malaria on our healthcare system and economy is immense," said Dr. Jimmy Opigo, the program manager of the Malaria Control Program at the Ministry of Health. "Every year, we lose thousands of lives, mostly children, to a disease that is preventable and now, through vaccination, even more manageable."
The vaccine rollout will initially focus on 105 districts with high and moderate malaria transmission rates, with plans to expand nationwide.
The northern and northeastern regions of Uganda, which have the highest malaria burden, will be among the first to receive the vaccine.
"This is a game-changer for malaria control in Uganda," Dr. Opigo emphasised. "We are the first country to implement this vaccine on such a large scale, and we are optimistic about its impact in reducing severe malaria cases and deaths."
Malaria transmission occurs when an infected Anopheles mosquito bites a person, injecting Plasmodium parasites into the bloodstream.
These parasites travel to the liver, multiply, and then infect red blood cells, leading to symptoms such as fever, chills, and anemia.
Sign up for free AllAfrica Newsletters
Get the latest in African news delivered straight to your inbox
"The malaria vaccine helps prime the immune system to fight the parasite before it can cause severe illness," explained Dr. Opigo. "It is not a standalone solution, but when combined with existing interventions like mosquito nets and indoor spraying, we expect a significant reduction in malaria cases."
The R21/Matrix-M vaccine will be administered in four doses at 6, 7, 8, and 18 months of age, targeting children under two years old. This schedule is designed to provide optimal protection during the most vulnerable stages of early childhood.
"We urge parents to ensure their children receive all four doses," said Dr. Opigo. "The vaccine is most effective when the full schedule is completed."
The rollout of the malaria vaccine is a joint effort between the Ugandan government and global health organizations, including Gavi, the Vaccine Alliance, UNICEF, and the World Health Organization (WHO).
"This is a major step toward malaria elimination," said a WHO representative in Uganda. "The introduction of the vaccine, alongside traditional malaria control measures, brings us closer to a future where malaria is no longer a leading cause of death in Uganda."
As Uganda embarks on this ambitious vaccine rollout, health officials remain hopeful that it will significantly reduce the malaria burden.
"The malaria vaccine is a beacon of hope for Uganda," said Dr. Opigo. "It will save countless lives and protect future generations from a disease that has plagued us for too long."
